中西医结合心脑血管病杂志
中西醫結閤心腦血管病雜誌
중서의결합심뇌혈관병잡지
CHINESE JOURNAL OF INTEGRATIVE MEDICINE ON CARDIO-/CEREBROVASCULAR DISEASE
2015年
4期
460-463
,共4页
张萍%吴立旗%杨虹婕%李博%徐凤芹%马晓昌
張萍%吳立旂%楊虹婕%李博%徐鳳芹%馬曉昌
장평%오립기%양홍첩%리박%서봉근%마효창
冠心病%室性早搏%参松养心胶囊%系统评价
冠心病%室性早搏%參鬆養心膠囊%繫統評價
관심병%실성조박%삼송양심효낭%계통평개
coronary artery disease%ventricular premature complexes%Shensong Yangxin capsule%systematic review
目的：评价参松养心胶囊治疗冠心病室性早搏的有效性及安全性。方法计算机检索 PubMed、Cochrane图书馆临床试验注册数据库、中国生物医学文献数据库(Web版)、中文生物医学期刊数据库(Web版)CMCC、VIP中文科技期刊数据库(Web版)、CNKI中国期刊全文数据库(Web版)、万方数据库,筛选参松养心胶囊治疗冠心病室性早搏的随机对照试验(RCT)或半随机对照试验。用 Jadad评分对纳入研究报告质量进行评价,RevMan5.1.4软件进行 Meta分析。结果共检索到有关参松养心胶囊的文献51篇,经过初筛和严格评价,符合纳入标准的15篇,最终进入 Meta分析共3篇。3项研究均比较了参松养心胶囊和心律宁片(苦参碱制剂)治疗冠心病室性早搏的疗效、心电图疗效、中医证候疗效及不良反应情况。纳入研究的 Jadad评分≥3分。对3项研究的室性早搏有效率合并效应量检验,PP分析结果：RR(fixed)=1.37,95%CI (1.18,1.59),P<0.0001；ITT分析结果：RR(fixed)=1.31,95%CI (1.15,1.54),P<0.0001。心电图疗效评价显示：RR(fixed)=1.48,95%CI (1.15,1.90),P=0.002。中医证候疗效显示：RR (fixed)=1.34,95%CI (1.21,1.49),P<0.0001。结论参松养心胶囊可能为一种治疗冠心病室性早搏的有效药物,但尚需要更多高质量研究以增加证据的强度。
目的：評價參鬆養心膠囊治療冠心病室性早搏的有效性及安全性。方法計算機檢索 PubMed、Cochrane圖書館臨床試驗註冊數據庫、中國生物醫學文獻數據庫(Web版)、中文生物醫學期刊數據庫(Web版)CMCC、VIP中文科技期刊數據庫(Web版)、CNKI中國期刊全文數據庫(Web版)、萬方數據庫,篩選參鬆養心膠囊治療冠心病室性早搏的隨機對照試驗(RCT)或半隨機對照試驗。用 Jadad評分對納入研究報告質量進行評價,RevMan5.1.4軟件進行 Meta分析。結果共檢索到有關參鬆養心膠囊的文獻51篇,經過初篩和嚴格評價,符閤納入標準的15篇,最終進入 Meta分析共3篇。3項研究均比較瞭參鬆養心膠囊和心律寧片(苦參堿製劑)治療冠心病室性早搏的療效、心電圖療效、中醫證候療效及不良反應情況。納入研究的 Jadad評分≥3分。對3項研究的室性早搏有效率閤併效應量檢驗,PP分析結果：RR(fixed)=1.37,95%CI (1.18,1.59),P<0.0001；ITT分析結果：RR(fixed)=1.31,95%CI (1.15,1.54),P<0.0001。心電圖療效評價顯示：RR(fixed)=1.48,95%CI (1.15,1.90),P=0.002。中醫證候療效顯示：RR (fixed)=1.34,95%CI (1.21,1.49),P<0.0001。結論參鬆養心膠囊可能為一種治療冠心病室性早搏的有效藥物,但尚需要更多高質量研究以增加證據的彊度。
목적：평개삼송양심효낭치료관심병실성조박적유효성급안전성。방법계산궤검색 PubMed、Cochrane도서관림상시험주책수거고、중국생물의학문헌수거고(Web판)、중문생물의학기간수거고(Web판)CMCC、VIP중문과기기간수거고(Web판)、CNKI중국기간전문수거고(Web판)、만방수거고,사선삼송양심효낭치료관심병실성조박적수궤대조시험(RCT)혹반수궤대조시험。용 Jadad평분대납입연구보고질량진행평개,RevMan5.1.4연건진행 Meta분석。결과공검색도유관삼송양심효낭적문헌51편,경과초사화엄격평개,부합납입표준적15편,최종진입 Meta분석공3편。3항연구균비교료삼송양심효낭화심률저편(고삼감제제)치료관심병실성조박적료효、심전도료효、중의증후료효급불량반응정황。납입연구적 Jadad평분≥3분。대3항연구적실성조박유효솔합병효응량검험,PP분석결과：RR(fixed)=1.37,95%CI (1.18,1.59),P<0.0001；ITT분석결과：RR(fixed)=1.31,95%CI (1.15,1.54),P<0.0001。심전도료효평개현시：RR(fixed)=1.48,95%CI (1.15,1.90),P=0.002。중의증후료효현시：RR (fixed)=1.34,95%CI (1.21,1.49),P<0.0001。결론삼송양심효낭가능위일충치료관심병실성조박적유효약물,단상수요경다고질량연구이증가증거적강도。
Objective To assess the effectiveness and safety of Shensong Yangxin capsule(SYC)in the treatment of ventricular pre-mature complexes(VPC)in coronary artery disease(CAD).Methods We searched the literature associated with randomized con-trol ed trials(RCT)or quasi RCT of traditional Chinese medicine(TCM)in treating CAD patients with VPC from PubMed(update to Feb 2011),Chinese Biology Medicine disc For Internet (CBM Web)(update to Feb 2011),Chinese Medical Current Content (CM-CC)(update to Feb 2011),VIP Chinese science and Technology Periodical Database (update to Feb 2011),CNKI China Journal Ful text Database(update to Feb 2011),and Wan Fang Database(update to Feb 2011).Quality of them was evaluated by the meth-od—Jadad score,and statistical analysis was performed using the Cochrane Col aboration’s Rev Man 5.1.4 software.Results The treated group was given SYC,while the control group was given matrine tablet in al the three trials.And they al compared the effec-tiveness,ECG effectiveness,syndrome of traditional Chinese Medicine and safety.Al the included were greater than or equal to score three (Jadad score).The combined effect of inspection about VPC effectiveness showed as fol ow.Per protocol analysis showed RR(fixed)= 1.37,95%CI (1.18,1.59),P<0.000 1.Intention to treat analysis showed RR(fixed)= 1.31,95%CI (1.15,1.54),P<0.000 1. ECG effectiveness shoued that RR(fixed)= 1.48,95%CI (1.15,1.90),P= 0.002.Syndrome of TCM:RR(fixed)= 1.34,95%CI (1.21,1.49), P<0.000 1.Conclusion According to the present evidence,SYC is effective in the treatment of VPC in CAD.But more wel designed randomized control ed trials are required.
